Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.33 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14843025 | 0.81 | ALDH1A1 (0.30) | — | |
| SCHEMBL30870656 | 0.81 | PARP1 (0.40) | PARP1PARP3PARP15TNKSTNKS2 | |
| SCHEMBL633261 | 0.70 | ACHE (0.43) | — | |
| SCHEMBL30777931 | 0.70 | ACHE (0.43) | — | |
| SCHEMBL29466623 | 0.70 | MAPK1 (0.47) | — | |
| SCHEMBL1819184 | 0.70 | MAPK1 (0.47) | — | |
| SCHEMBL23816987 | 0.68 | MAPK1 (0.46) | — | |
| SCHEMBL31095398 | 0.68 | MAPK1 (0.46) | — | |
| SCHEMBL16136206 | 0.68 | MAPK1 (0.46) | — | |
| SCHEMBL15831715 | 0.68 | MAPK1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165003-B | Thiopyranopyrimidine-containing compounds and application thereof | 江西科技师范大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-118165003-A | Thiopyranopyrimidine-containing compounds and application thereof | 江西科技师范大学 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-116239603-A | 2-aminopyrimidine heterocyclic compound and application thereof | 江西科技师范大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-111732597-B | Preparation and application of 2-aminopyrimidine heterocyclic compound containing 4-amidophenoxy | 江西科技师范大学 | 2022-11-01 | — | — | CN | disclosed |
| CN-113880859-B | 2-aryl-4-arylmethylamino pyrimidine compound and application thereof | 江西科技师范大学 | 2022-06-21 | — | — | CN | disclosed |
| CN-113880859-A | 2-aryl-4-arylmethylamino pyrimidine compound and application thereof | 江西科技师范大学 | 2022-01-04 | — | — | CN | disclosed |
| CN-111732597-A | Preparation and application of 2-aminopyrimidine heterocyclic compound containing 4-amidophenoxy | 江西科技师范大学 | 2020-10-02 | — | — | CN | disclosed |
| EP-2763985-B1 | {(4-(4-MORPHOLINO-DIHYDROTHIENO[3,4-D]PYRIMIDIN-2-YL)ARYL}UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| EP-2763985-B1 | {(4-(4-MORPHOLINO-DIHYDROTHIENO[3,4-D]PYRIMIDIN-2-YL)ARYL}UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LTD (GB) | 2016-06-22 | — | — | EP | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242993-B2 | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2763985-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013050508-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
| WO-2013050508-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288066-A1 | MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, CCNT1 | PARP1 1714/4885PARP3 1261/4885PARP15 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.